- Home
- KNSA vs BCRX Comparison
KNSA vs BCRX Comparison
Compare KNSA & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- BCRX
- Stock Information
- Founded
- KNSA 2015
- BCRX 1986
- Country
- KNSA United Kingdom
- BCRX United States
- Employees
- KNSA N/A
- BCRX N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNSA Health Care
- BCRX Health Care
- Exchange
- KNSA Nasdaq
- BCRX Nasdaq
- Market Cap
- KNSA 1.5B
- BCRX 1.7B
- IPO Year
- KNSA 2018
- BCRX 1994
- Fundamental
- Price
- KNSA $20.21
- BCRX $7.40
- Analyst Decision
- KNSA Strong Buy
- BCRX Buy
- Analyst Count
- KNSA 6
- BCRX 6
- Target Price
- KNSA $37.17
- BCRX $15.67
- AVG Volume (30 Days)
- KNSA 638.0K
- BCRX 3.2M
- Earning Date
- KNSA 04-29-2025
- BCRX 05-05-2025
- Dividend Yield
- KNSA N/A
- BCRX N/A
- EPS Growth
- KNSA N/A
- BCRX N/A
- EPS
- KNSA N/A
- BCRX N/A
- Revenue
- KNSA $423,239,000.00
- BCRX $450,712,000.00
- Revenue This Year
- KNSA $37.21
- BCRX $27.64
- Revenue Next Year
- KNSA $2.58
- BCRX $13.42
- P/E Ratio
- KNSA N/A
- BCRX N/A
- Revenue Growth
- KNSA 56.60
- BCRX 36.00
- 52 Week Low
- KNSA $16.56
- BCRX $4.03
- 52 Week High
- KNSA $28.15
- BCRX $9.50
- Technical
- Relative Strength Index (RSI)
- KNSA 44.56
- BCRX 50.46
- Support Level
- KNSA $18.26
- BCRX $6.02
- Resistance Level
- KNSA $21.24
- BCRX $7.41
- Average True Range (ATR)
- KNSA 1.12
- BCRX 0.44
- MACD
- KNSA -0.12
- BCRX 0.06
- Stochastic Oscillator
- KNSA 44.43
- BCRX 81.66
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.